Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?

doi:10.1186/ar2490

Arthritis Research & Therapy

Volume 10
Issue 5

Viewing options:

Abstract
Full text
PDF (41KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Dougados M

on PubMed

Dougados M
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Editorial

Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?

Maxime Dougados

Paris-Descartes University, Medicine Faculty; UPRES-EA 4058; AP-HP, Cochin Hospital, Rheumatology B Department, Paris, France

author email corresponding author email

Arthritis Research & Therapy 2008, 10:116doi:10.1186/ar2490


Published:	19 September 2008

See related research by Raychaudhuri et al., http://arthritis-research.com/content/10/4/R85

Abstract

5-Loxin^®is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound.